A ratiometric imaging platform to advance COVID-19 counter measures

用于推进 COVID-19 应对措施的比例成像平台

• 批准号: 552990-2020
• 负责人: Ryan, Scott
• 金额: $ 3.64万
• 依托单位: University of Guelph
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=703927
• 关键词: ratiometric; imaging; platform; advance; COVID

COVID-19 is a severe acute respiratory syndrome (SARS) caused by infection of lung epithelial cells with the SARS coronavirus 2 (SARS-CoV-2). CoV replication requires the acidic environment of a cell compartment called the lysosome. As such, monitoring the lysosome accumulation may represent a means of studying viral replication and monitoring viral load. We propose to repurpose our considerable expertise and industry partnerships that were developed while studying lysosomes in neurodegenerative disease to develop, optimize and validate a fast, low-cost, high-throughput approach to measuring CoV accumulation and replication in the lysosomes of lung cells. The primary goals of this project are therefore, 1) to develop and optimize a microscopy-based measurement of SARS-CoV-2 levels in the lysosome 2) to develop a module for a widely used microscopy software that will enable fast, accurate measurement of SARS-CoV-2 replication, and 3) to validate that this new tool permits the study of CoV replication. To do this, we have partnered with Quorum Technologies, a Canadian owned enterprise located in Guelph, Ontario that develops microscopes and microscopy-software for the life sciences. The ratiometric imaging software module we develop will also be used to conduct proof-of-principle tests that will determine whether the system accurately measures SARS-CoV-2 replication. Given diagnostic and prognostic measures of viral load in COVID-19 patients are sorely lacking and urgently needed, the proposed work represents an important step towards accelerating COVID-19 countermeasures.

COVID-19 是一种严重急性呼吸综合征 (SARS)，由 SARS 冠状病毒 2 (SARS-CoV-2) 感染肺上皮细胞引起。冠状病毒的复制需要称为溶酶体的细胞区室的酸性环境。因此，监测溶酶体积累可能是研究病毒复制和监测病毒载量的一种手段。 我们建议重新利用我们在研究神经退行性疾病中的溶酶体时积累的大量专业知识和行业合作伙伴关系，以开发、优化和验证一种快速、低成本、高通量的方法来测量肺细胞溶酶体中 CoV 的积累和复制。因此，该项目的主要目标是：1) 开发和优化溶酶体中 SARS-CoV-2 水平的基于显微镜的测量 2) 为广泛使用的显微镜​​软件开发一个模块，该模块将能够快速、准确地测量SARS-CoV-2 复制，以及 3) 验证该新工具是否允许研究 CoV 复制。为此，我们与 Quorum Technologies 合作，Quorum Technologies 是一家位于安大略省圭尔夫的加拿大独资企业，专门为生命科学开发显微镜和显微镜软件。我们开发的比率成像软件模块还将用于进行原理验证测试，以确定系统是否准确测量 SARS-CoV-2 复制。鉴于严重缺乏且迫切需要对 COVID-19 患者病毒载量进行诊断和预后测量，拟议的工作代表了加速 COVID-19 对策的重要一步。